Tarek Mekhail, MD, MSc, FRCSI, FRCSEd


Medical Director, Thoracic Cancer Program, Florida Hospital Cancer Institute
Focuses on head and neck, lung cancers, and aero-digestive malignancies
Tarek Mekhail, MD

Dr. Tarek Mekhail is a lung, kidney and head and neck cancer specialist who is board certified in internal medicine, hematology and oncology. A medical team member at the Cancer Institute of Florida and Medical Director of the Thoracic Oncology Program at the Florida Hospital Cancer Institute. he also serves as an associate professor at the University of Central Florida’s medical school and previously served as director of the prestigious Cleveland Clinic’s Lung Cancer Medical Oncology Program. His outstanding clinical skills and exemplary patient outcomes have earned him “Best Doctor in America” and “Best Doctor in Cleveland” nods as well as other honors throughout his career.

Dr. Mekhail completed both his post-graduate fellowship and residency training at the prestigious Cleveland Clinic Foundation in Cleveland, Ohio, and has served as the Director of the Lung Cancer Medical Oncology Program and Chairman of Oncology Research at the Cleveland Clinic’s Taussig Cancer Center. He is a prolific researcher, clinical trial investigator and presenter at national conferences, with over 70 publications in peer-reviewed medical journals and seven book chapters to his name.


  • Gastrointestinal Cancers
  • Head and Neck Cancers
  • Lung Cancer

Awards & Honors

  • Cleveland Clinic Foundation Fellow of the Year Award Marquis Who’s Who® In America, 2011 and 2012
  • Best Doctors in America®, 2008, 2009, 2010 and 2011
  • Best Doctors in Orlando®, 2009, 2010 and 2011
  • Best Doctors in Cleveland®, 2004 through 2009
  • Teacher of the Year Award, Hematology/Medical Oncology Program, Cleveland Clinic, 2003/2004, 2004/2005, 2005/2006 and 2007/2008
  • Fellow of the Year Award, The Cleveland Clinic Foundation, 2001
  • Southwest Oncology Young Investigator Award, 2000


  • Exhaled Breath Analysis with a Colorimetric Sensor Array for the Identification and Characterization of Lung Cancer


  • Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer
  • The role of consolidation treatment in locally advanced unresectable NSCLC
  • Thymic neoplasms: a clinical update
  • Exhaled breath analysis with a colorimetric senson array for the identification and characterization of lung cancer
QOPI Certification Program

Points of Difference

  • Award-Winning Innovations
  • Care, Support and Spa Services
  • Clinical Trials
  • Destination Services
  • National Accreditations and Certifications
  • Nationally Ranked Cancer Programs

Results & Outcomes

  • Higher than Average Survival Rates
  • Advanced Diagnostics and Surgical Innovations
  • High Patient Satisfaction
  • Ongoing Research
  • Publications and Presentations
  • Ongoing Data, Results and Comparisons
(407) 966-4013